To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

This is an open-label, single dose, non-randomised, parallel group study. Participant will be enrolled in 3 cohorts. * Cohort 1 will include 8 participants with severe renal impairment (estimated glomerular filtration rate \[eGFR\] of ≥15 to \< 30 mL/min/1.73 m\^2). * Cohort 2 will include 8 healthy participants with normal renal function (eGFR of ≥ 90 mL/min/1.73 m\^2) that will serve as matched controls for Cohort 1 and Cohort 3. Matching will account for age, Body mass index (BMI), and gender. * Cohort 3 will include 8 participants with ESRD on dialysis (eGFR of \< 15 mL/min/1.73 m\^2). * Participants in Cohort 3 will receive a single dose of AZD8233 the day after haemodialysis. Participant will receive the study drug on Day 1, discharged on Day 2 followed by out-patient follow-up visits on Day 3, 7, 14, 28, 42, 56, and 90.